Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors

Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors

Abstract Background A limitation of approved oncolytic viruses is their requirement for intratumoral (i.t.) injection. TILT-123 (igrelimogene litadenorepvec, Ad5/3-E2F-D24-hTNFα-IRES-hIL-2) is a chimeric oncolytic adenovirus suitable for intravenous (i.v.) delivery due to its capsid modification and...

Full description

Saved in:
Bibliographic Details
Main Authors: Elise Jirovec, Dafne C. A. Quixabeira, James H. A. Clubb, Santeri A. Pakola, Tatiana Kudling, Victor Arias, Lyna Haybout, Katriina Jalkanen, Tuomo Alanko, Tine Monberg, Amir Khammari, Brigitte Dreno, Inge Marie Svane, Matthew S. Block, Daniel A. Adamo, Johanna Mäenpää, Claudia Kistler, Suvi Sorsa, Otto Hemminki, Anna Kanerva, João M. Santos, Victor Cervera-Carrascon, Akseli Hemminki
Format: Article
Language:English
Published: BMC 2024-11-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Oncolytic Virus
TILT-123
Intravenous Delivery
Adenovirus
Solid Tumors
Immunotherapy
Online Access:https://doi.org/10.1186/s13046-024-03219-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13046-024-03219-0

Similar Items